News

NOS2 Exhibits Therapeutic Potential in Mouse Study

Suppressing the production of an enzyme called nitric oxide synthase 2 (NOS2) led to reductions in alpha-synuclein-related abnormalities and neuroinflammation in a mouse model of Parkinson’s disease, a new study reports. “Our data indicate that NOS2 may be a therapeutic target for modulating [Parkinson’s disease] in the brain,” the…

FDA Lifts Hold on IkT-148009; Trial to Resume Soon

The U.S. Food and Drug Administration (FDA) has lifted its full clinical hold on IkT-148009, Inhibikase Therapeutics’ investigational oral therapy for Parkinson’s disease. The agency had placed a hold on all clinical trials of IkT-158009 in December, just a few months after Inhibikase had begun dosing Parkinson’s patients in a …

Exergame-based Program Shown to Be Feasible for Parkinson’s Rehab

A cognitive-motor training program featuring a video game platform that promotes exercise is feasible for people with Parkinson’s disease to use, a new study demonstrates. Patients using the program along with standard rehabilitation showed comparable and greater motor and cognitive improvements relative to those on standard rehabilitation alone. These preliminary…

Community Exercise May Help to Ease Parkinson’s Motor Symptoms

Taking part in a community-based exercise program appears to help relieve the motor symptoms of Parkinson’s disease, a review study suggests. Researchers also observed that older people and those engaging in these programs for longer periods may get the most benefit. The review study, “Effects and parameters of community-based…